JNJ Mar 2025 180.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:19AM EDT
| Previous close | 35.22 |
| Open | N/A |
| Bid | 33.80 |
| Ask | 36.80 |
| Strike | 180.00 |
| Expiry date | 2025-03-21 |
| Day's range | 35.22 - 35.22 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksJ&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
ZacksThe Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.
Business WireJohnson & Johnson Completes Acquisition of Proteologix, Inc.
NEW BRUNSWICK, N.J., June 21, 2024--Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024.
© 2024 Yahoo. All rights reserved.